TY - JOUR
T1 - Differences in bioactivity between human insulin and insulin analogues approved for therapeutic use- compilation of reports from the past 20 years
AU - Werner, Haim
AU - Chantelau, Ernst A.
N1 - Funding Information:
Work in the laboratory of HW is supported by a grant from Insulin Dependent Diabetes Trust (IDDT), UK.
PY - 2011
Y1 - 2011
N2 - In order to provide comprehensive information on the differences in bioactivity between human insulin and insulin analogues, published in vitro comparisons of human insulin and the rapid acting analogues insulin lispro (Humalog®), insulin aspart (NovoRapid®), insulin glulisine (Apidra®), and the slow acting analogues insulin glargine (Lantus®), and insulin detemir (Levemir®) were gathered from the past 20 years (except for receptor binding studies). A total of 50 reports were retrieved, with great heterogeneity among study methodology. However, various differences in bioactivity compared to human insulin were obvious (e.g. differences in effects on metabolism, mitogenesis, apoptosis, intracellular signalling, thrombocyte function, protein degradation). Whether or not these differences have clinical bearings (and among which patient populations) remains to be determined.
AB - In order to provide comprehensive information on the differences in bioactivity between human insulin and insulin analogues, published in vitro comparisons of human insulin and the rapid acting analogues insulin lispro (Humalog®), insulin aspart (NovoRapid®), insulin glulisine (Apidra®), and the slow acting analogues insulin glargine (Lantus®), and insulin detemir (Levemir®) were gathered from the past 20 years (except for receptor binding studies). A total of 50 reports were retrieved, with great heterogeneity among study methodology. However, various differences in bioactivity compared to human insulin were obvious (e.g. differences in effects on metabolism, mitogenesis, apoptosis, intracellular signalling, thrombocyte function, protein degradation). Whether or not these differences have clinical bearings (and among which patient populations) remains to be determined.
UR - http://www.scopus.com/inward/record.url?scp=79959650451&partnerID=8YFLogxK
U2 - 10.1186/1758-5996-3-13
DO - 10.1186/1758-5996-3-13
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.systematicreview???
C2 - 21714872
AN - SCOPUS:79959650451
SN - 1758-5996
VL - 3
JO - Diabetology and Metabolic Syndrome
JF - Diabetology and Metabolic Syndrome
IS - 1
M1 - 13
ER -